Kidney Week

Abstract: FR-PO516

Caffeine Consumption and Mortality in CKD

Session Information

• CKD: Epidemiology, Outcomes - Non-Cardiovascular - I
  November 03, 2017 | Location: Hall H, Morial Convention Center
  Abstract Time: 10:00 AM - 10:00 AM

Category: Chronic Kidney Disease (Non-Dialysis)

• 304 CKD: Epidemiology, Outcomes - Non-Cardiovascular

Authors

• Bigotte Vieira, Miguel, Centro Hospitalar Lisboa Norte, Lisboa, Portugal

Miguel Bigotte Vieira,

• Magriço, Rita, Hospital Garcia de Orta, Almada, Portugal

Rita Magriço,

• Viegas dias, Catarina, Dafundo Family Health Unit, Lisbon, Portugal

Catarina Viegas dias,

• Leitão, Lia, Hospital Prof. Doutor Fernando Fonseca, Amadora, Portugal

Lia Leitão,

• Neves, João Sérgio, São João Hospital, Faculty of Medicine, University of Porto, Portugal, Porto, Portugal

João Sérgio Neves,

Background

An inverse relationship between coffee consumption and mortality has been reported in the general population. However, the association between caffeine consumption and mortality in patients with CKD remains unclear.

Methods

We examined the association of caffeine consumption with mortality among 2328 patients with CKD (defined by estimated GFR < 60 mL/min/1.73m², CKD-EPI) in a prospective nationwide cohort, using the continuous National Health and Nutrition Examination Survey (NHANES) 1999-2010. Caffeine consumption was assessed at baseline using 24-hour dietary recalls. Cox proportional hazard models were fitted to estimate hazard ratios (HR) for all-cause mortality according to quartiles of caffeine consumption, adjusting for potential confounders (age, gender, race, annual family income, education level, estimated GFR, albumin/creatinine ratio, hypertension, smoking status, dyslipidemia, body mass index, previous cardiovascular events and diet: consumption of alcohol, carbohydrates, polyunsaturated fatty acids and fibers). We assessed the extent to which CKD stage modified the effects of caffeine consumption on mortality with likelihood ratio tests for interaction.

Results

Quartiles of caffeine consumption were: 1^st quartile (<29.5 mg of caffeine/day), 2^nd (30.5 to 101.0 mg/day), 3^rd (101.5 to 206.0 mg/day), and 4^th quartile (206.5 to 1378.5 mg/day). A dose-dependent inverse association between caffeine and all-cause mortality was observed in patients with CKD. Comparing with 1^st quartile of caffeine consumption, adjusted HR for death was 0.88 (95% CI, 0.68-1.44) for 2^nd quartile, 0.78 (95% CI, 0.60-1.01) for 3^rd quartile and 0.76 (95% CI, 0.59-0.97) for 4^th quartile (p=0.027 for trend across quartiles). There were no significant interactions between caffeine consumption quartiles and CKD stages with respect to all-cause mortality.

Conclusion

Our study showed a dose-dependent protective effect of caffeine consumption on mortality among patients with CKD.